Abbott Laboratories agreed to settle claims from a laid-off worker that the company engaged in pregnancy discrimination by ...

DexCom and Abbott resolve patent litigation with a cross-licensing agreement, ending disputes without royalties or financial ...

The latest trading session saw Abbott (ABT) ending at $114.31, denoting a +0.07% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of 0.73%. Meanwhile, ...

The companies have been involved in global patent litigation, with both having accused the other of infringing certain ...

Shares of Abbott Laboratories ABT inched 0.39% higher to $114.76 Tuesday, on what proved to be an all-around positive trading ...

Wells Fargo notes Abbott (ABT) and DexCom (DXCM) have disclosed that on December 20, they settled and entered into a cross-license agreement to ...

A federal appeals court trimmed a whistleblower’s once-defeated False Claims Act suit Friday alleging Abbott Laboratories Inc ...

Dec 23 (Reuters) - Abbott Laboratories (ABT.N), opens new tab and DexCom (DXCM.O), opens new tab said on Monday they have reached an agreement to settle all patent disputes between them related to ...

Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $114.23 which represents a slight increase of $1.81 or 1.61% from the prior close of $112.42. The stock opened at $112.64 and ...

By: Ricardo E. Calderon, Eagle Pass Business Journal, Inc., Copyright 2024 Texas Governor Greg Abbott announced at a press ...

As previously disclosed, DexCom has been involved in global patent litigation with Abbott Diabetes Care and its affiliates. Both the Comp ...